inx-315
(2)Legend
Company
Founder · Executive · Scientist
Patrick Roberts Is Betting the Cell Cycle Has Another Door
After helping a small North Carolina biotech move a cell-cycle drug from discovery toward patients, Patrick Roberts reunited with longtime colleagues to pursue a harder target: CDK2. The wager behind Incyclix Bio is that precision, patience and the right biomarkers can reopen a route that resistant cancers have learned to use.
patrick-roberts · incyclix-bioRead →
Health
Incyclix Bio Is Betting One Precise Brake Can Stop Cancer's Second Escape Route
A 13-person North Carolina biotech licensed an overlooked CDK2 program, narrowed the patient target and pushed one oral drug into the clinic. Early data offer a reason to keep going - and a useful blueprint for building around a precise scientific thesis rather than a sprawling pipeline.
biotechnology · oncologyRead →